Advanced Therapies Europe 2026

Advanced Therapies Europe 2026, evento organizado por Phacilitate, tendrá lugar del 7 al 9 de septiembre de 2026 en Barcelona.
 

No se puede perder la oportunidad de participar en un evento clave que reúne a líderes europeos en terapias avanzadas, así como a expertos, desarrolladores y reguladores, para debatir sobre las últimas novedades en la investigación, desarrollo y comercialización de terapias celulares, génicas y regenerativas.

Advanced Therapies Europe ofrece una plataforma única para la colaboración, el intercambio de conocimientos y la creación de sinergias que impulsan el futuro de la medicina personalizada e innovadora.

Los temas de interés en Advanced Therapies Europe incluyen la inversión en biotecnología, con un enfoque en las oportunidades para startups y fondos, y el liderazgo femenino e inclusividad en el sector. Se debatirán los retos de la escala y producción de terapias génicas y celulares, especialmente en la manufactura de AAV, y se explorarán las normativas europeas y los desafíos regulatorios. Además, se tratarán temas clave como el acceso a tratamientos para los pacientes y la industrialización de terapias celulares, buscando superar las barreras para su implementación clínica.

Tanto si estás lanzando una nueva terapia, buscando asociaciones estratégicas o queriendo anticiparte a los cambios regulatorios y del mercado, Advanced Therapies Europe está diseñado para ofrecerte información práctica y conexiones significativas.

• Expande tu red – Conoce a CEOs de biotecnología, estrategas farmacéuticos, líderes de CDMO e inversores que están moldeando la próxima ola de innovación terapéutica.
• Gana perspectiva estratégica – Accede a sesiones dirigidas por expertos de la industria sobre regulación, tendencias de financiación, soluciones para escalar y estrategia comercial.
• Descubre lo que hay en el futuro – Explora los últimos avances en plataformas de terapia celular y génica, tecnologías biotecnológicas y medicina regenerativa.

Las empresas y entidades de la BioRegión de Catalunya, pueden disfrutar de un 20% de descuento utilizando el código BIOCAT20 en el momento de la inscripción.

07/09/2026

09:15h - 09:55h | Theatre 1&2

What it takes to fund advanced therapies in 2026

• Artemy Shumskiy, Principal - LongeVC
• Gadareth Higgs, Partner - Advantary Capital Partners
• Laura Rodriguez, Partner - Invivo Partners
• Malgorzata Rogalska, Analyst - Ysios Capital
• Rahul Khetan, Venture Associate - UCB Ventures

09:55h - 10:35h | Theatre 1&2

Panel: Alternative funding models and capital structures for biotech

• Angel Lucio, CEO - TETRANEURON
• Claudio Santos, CEO - Gyala Therapeutics
• Kiren Baines Mortimore, CEO & Co-Founder - Valaya Bio
• Michael Meyers, Vice Chairman, Head of M&A and Strategic Advisory Services - HC Wainwright & Co

11:05h - 11:45h | Theatre 1&2

Differentiation or bust: How to stand out in a saturated market

• Faizzan Ahmed, Managing Partner - YZR Capital Biotech
• Ana Duran, Associate - LifeLink Ventures
• Jose Mesa, Partner - Columbus Venture Partners
• Marc Ramis Castelltort, Founder & Managing Partner - Montana
• Matt Symes, Investor - Delin Ventures

11:45h - 12:15h | Theatre 1&2

Fireside Chat: What “investment ready” looks like in 2026

• Avencia Sanchez-Mejias, CEO & Co-Founder - Integra Therapeutics

• Luis Pareras, Managing Partner - Invivo Partners

   

13:40h - 14:10h | Workshop Room

Fireside chat: We’ve heard the challenges. Now, what are we changing?

• Ingrid Marchal-Gerez, Director, EMEA Cell Therapy Commercial Operations - Johnson & Johnson
• Lynette James, VP Supply Chain & External Manufacturing - Quell Therapeutics
• Montse Daban, Director of Strategic Foresight and International Relations - Biocat
• Vasiliki Kalodimou, Assistant Professor - European University Cyprus

15:15h - 16:15h | Workshop Room

Roundtable: The power of community: Building your industry network

• Margot Pont, VP Translational Development - Integra Therapeutics

15:15h - 16:15h | Theatre 1&2

Roundtable: Non-linear career paths: Leveraging unique journeys

• Cristina Salado, Assistant Professor - Universitat Pompeu Fabra

   

08/09/2026

09:15h - 09:50h | Theatre 1&2

Europe’s ATMP rulebook reset: The 12-month pathway from fragmented rules to trusted EU execution

• Esteve Trias, ATMP Expert
• Jacob George, Chief Medical & Scientific Officer - MHRA
• Robert Allen, Chief Business Officer - Dark Horse Consulting

• Sean Russell, Head of Regulatory Affairs – Fondazione Telethon

   

9:50h - 10:30h | Theatre 1&2

Panel: Europe’s Roadmap Winning the Next Wave of ATMP R&D: What Europe must resolve to compete on speed, scale and return

• Bo Wiinberg, CBO - Novo Nordisk Foundation Cellerator
• Jacqueline Barry, Chief Clinical Officer – Cell and Gene Therapy Catapult
• Jim Lund, Chief Business Development Officer - CCRM Nordic
• Miguel Forte, CEO - Kiji Therapeutics
• Montse Daban, Director of Strategic Foresight and International Relations - Biocat
• Paolo Morgese, Vice President Public Affairs, Europe - Alliance for Regenerative Medicine

12:15h - 12:45h | Theatre 1

CGT clinical trials at pace: What’s accelerating, what’s stuck and how Europe turns trials into treatments

• Cristina Salado, Assistant Professor - Universitat Pompeu Fabra
• Joana Claverol, Head of Clinical Research Unit - Sant Joan de Deu
• Manel Juan Otero, Head of Immunology - Hospital Clínic de Barcelona
• Sean Russell, Head of Regulatory Affairs - Fondazione Telethon

13:00h - 14:00h | Workshop Room

Panel: Designing advanced therapies that survive scale: from early decisions to commercial readiness

• Emmanuelle Cameau, Scientific Director Genomic Medicine - Cytiva
• Esteve Trias, ATMP Expert
• Margot Pont, VP Translational Development - Integra Therapeutics
• Núria Gavaldà, ATMP Platform Director - Banc de Sang i Teixits (Blood and Tissue Bank)

15:00h - 15:15h | Theatre 1

Spotlight: A new lentiviral vector for in vivo CAR-T with high specificity and efficacy for multi-immune cell targeting

• Stefanos Theoharis, CEO - OneChain Immunotherapeutics

   

15:15h - 16:00h | Theatre 1

Panel: The in vivo inflection: From breakthrough to clinical momentum, how far and how fast can this wave go?

• Andrew Frazer, Associate Director, Scientific Solutions - Rose BioSolutions
• Margot Pont, VP Translational Development - Integra Therapeutics
• Maria Eugenia Alonso Ferrero, Immunogenecity Science Director - Alexion Pharmaceuticals
• Stefanos Theoharis, CEO - OneChain Immunotherapeutics

15:30h - 16:00h | Theatre 2

Panel: From scaled to standard of care: commercialising CGTs across Europe’s fragmented health systems

• Angela Borghouts de Ruijter, Associate Director Market Access - Gilead
• Esteve Trias, ATMP Expert
• Francis Pang, Senior Vice President, Global Market Access and International Geographic Expansion - Orchard Therapeutics
• Tamara Loos, Consultant - ENIMAXE

16:30h - 17:30h | Workshop Room

When venture philanthropy meets venture creation 

• Gonzalo Fernandez-Miranda, Co-founder & CEO - CureAge Therapeutics

   

16:30h - 17:30h | Workshop Room

Roundtable: Cracking the EU Code: Turning regulatory & supply complexities into a smooth process

• Cristina Salado, Assistant Professor - Universitat Pompeu Fabra

   

16:30h - 17:30h | Workshop Room

Roundtable: Managing immunogenicity risk across the next generation of advanced therapies

• Maria Eugenia Alonso Ferrero, Immunogenecity Science Director - Alexion Pharmaceuticals

   

09/09/2026

09:00h - 10:30h |  Theatre 1

Innovation Exchange

• Gadareth Higgs, Partner - Advantary Capital Partners
• Malgorzata Rogalska, Analyst - Ysios Capital
• Matt Symes, Investor - Delin Ventures

• Rahul Khetan, Venture Associate - UCB Ventures

   

10:30h - 11:15h |  Theatre 1

Designing CGTs in the age of agentic AI: How to accelerate discovery and development without losing regulatory control

• Aneta Tyszkiewicz, Director Data Digital - EFPIA - European Federation of Pharmaceutical Industries and Associations
• Clara Cuervo, Head of AI and Digital Transformation Cell Therapy Clinical Operations Global - AstraZeneca
• Domitille Halie, Head of Scientific Project Management - WhiteLab Genomics
• Marc Guell, Cofounder & Scientific Head - Integra Therapeutics
• Vasiliki Kalodimou, Assistant Professor - European University Cyprus

12:15h - 12:30h |  Theatre 1

Spotlight: A first-in-class CAR-T cell therapy for HER2 resistant solid tumors

• Judit Anido, Business Lead - EraCell

   

12:30h - 12:45h |  Theatre 1

Spotlight: Public–private partnership models that combine academic, clinical, and industry strengths to accelerate translation of advanced therapies

• Simon de Miquel, Strategic Project Manager & Business Developer - Advanced Therapies - Barcelona Children's Hospital Sant Joan de Deu

   

12:45h - 13:30h |  Theatre 1

Panel: Access is the real innovation: How Europe turns breakthroughs into therapies patients can actually receive

• Alessandra Magnani, Head of Advanced Therapies and Immunotherapy Platform - Hospital Sant Joan de Déu 
• Ingrid Marchal-Gerez, Director, EMEA Cell Therapy Commercial Operations - Johnson & Johnson
• Marion Hitchcock, Managing Director Gene & Cell Therapies Incubator Berlin and R&D Strategy & Portfolio Manager - Bayer
• Mark Flower, VP of Business Development, Cell and Gene Technologies - AGC Biologics

• Sonja Steppan - Fresenius Group

   

13:30h - 14:30h |  Workshop Room

From Early Development to Commercial Readiness: Real-World Lessons in Advancing Lentiviral-Based Therapies

• Miguel Forte, CEO - Kiji Therapeutics
• Natalia Elizalde - VIVEbiotech

• Willem-Jan Krebber, Chief Development Officer - Genewity Holding B.V

   

15:25h - 16:05h |  Theatre 1

Panel: Modalities and markets at the crossroads - Where advanced therapies go next and how Europe chooses to compete

• Bernd Eschgfäller, Board Member - T-CURX
• Carolina Pola, CEO - STAb Therapeutics
• Khalid Shah, Director, Center of Stem Cell and Translational Immunotherapy - Brigham and Women's Hospital
• Ricardo Baptista, CTO - SmartCella
• Robert Fabregat Fuentes, CEO - Biocat

El pasado 15 de julio, Advanced Therapies Europe organizó el webinar “Europe’s ATMP Roadmap: From Strategy to Execution in a New Global Reality”, una sesión previa para debatir los retos de Europa en innovación, fabricación y ensayos clínicos en terapias avanzadas.

Participó Montse Daban, directora de Estrategia y Alianzas Globales de Biocat, junto con Miguel Forte, CEO de Kiji Therapeutics, y Paolo Morgese, VP Public Affairs Europe de la Alliance for Regenerative Medicine.